Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.160
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
3.200
+0.040 (1.27%)
After-hours: Mar 27, 2026, 4:12 PM EDT
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$491,849
Profits / Employee
-$1,081,343
Market Cap
59.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 9 | -1 | -10.00% |
| Jun 30, 2024 | 10 | -1 | -9.09% |
| Jun 30, 2023 | 11 | -1 | -8.33% |
| Jun 30, 2022 | 12 | 1 | 9.09% |
| Jun 30, 2021 | 11 | -1 | -8.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| MindWalk Holdings | 102 |
| Adicet Bio | 102 |
| ImmuCell | 84 |
| eXoZymes | 31 |
| iBio, Inc. | 20 |
| Annovis Bio | 15 |
| ImageneBio | 15 |
ATHE News
- 20 days ago - Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit - GlobeNewsWire
- 25 days ago - Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor - Nasdaq
- 27 days ago - Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments - GlobeNewsWire
- 2 months ago - Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 4 months ago - Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - GlobeNewsWire
- 5 months ago - Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - GlobeNewsWire
- 6 months ago - Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 6 months ago - Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire